Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer
Brief description of study
The goal of this Phase II study is to evaluate the safety/tolerability and clinical activity of the combination of nab-paclitaxel and the antibody against programmed cell death 1 (PD-1), pembrolizumab, in patients with human epidermal growth factor receptor (HER-2) negative metastatic breast cancer (n=50). There will be a cohort of patients consisting of a triple negative breast cancer (TNBC) cohort with 50 subjects. Tumor expression of programmed cell death ligand 1 (PD-L1) is not required for enrollment in the study, but will be assessed as possible predictive marker. Enrollment of patients with metaplastic breast cancer is encouraged.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
